Latest news and press releases about Upstream Bio, Inc. (UPB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
Price
| Price | $5.33 |
| Market Cap | $290M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.06 |
| EV / EBITDA | -9.51 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -42.22% |
| Return on Invested Capital | -47.02% |
| Return on Assets | -40.55% |
| Gross Margin | 98.45% |
| Operating Margin | -5382.65% |
| Net Margin | -4955.67% |
Related companies: AMLX · NTLA · NVAX · PHVS · RLAY · SNDX · SYRE
Explore sector: Healthcare · Biotechnology
More sections of UPB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks